Peter Kolovos concentrates his practice on securities litigation and enforcement matters, as well as corporate and complex commercial litigation. He has represented numerous public companies and their officers and directors in federal and state securities litigation and enforcement matters, including securities fraud class actions, derivative litigation, and SEC, DOJ and other federal and state regulatory investigations. He also has conducted internal investigations for companies in a variety of industries on issues such as revenue recognition, options backdating, and earnings management. His practice also has included a wide range of other complex litigation matters, including mergers and acquisitions disputes, closely-held corporation disputes, intellectual property litigation and commercial real estate disputes.

Experience

    • Obtained dismissal for a clinical-stage life sciences company of a federal securities fraud class action arising from announcement of disappointing results of a Phase 3 clinical trial
    • Obtained dismissal for a medical device company of a federal securities fraud class action arising from a product recall
    • Obtained denial of class certification in a federal securities fraud class action for a life sciences company based upon a showing of inadequacy of lead counsel and atypicality of lead plaintiffs
    • Successful defense of a medical device company and its officers in a securities fraud class action involving allegations of channel stuffing and improper revenue recognition
    • Successful representation of a healthcare services provider and its officers and directors in a class action alleging breaches of fiduciary duties in connection with a merger transaction
    • Successful representation of a pharmaceutical company in a federal securities fraud class action arising from the company's statements about a drug candidate's prospects for FDA approval
    • Successful defense of a telecommunications company and its officers in obtaining dismissal of two securities fraud class actions
    • Successful representation of a real estate investment and management company and its officers and directors in a class action alleging breaches of fiduciary duties in connection with a "going private" merger
    • Successful defense through trial, appeal, and certiorari to the United States Supreme Court of an investment company in a fiduciary duty and conspiracy action involving a closely-held corporation
    • Representation of companies in a variety of industries, including manufacturing, technology, defense, insurance, software, and healthcare, in class actions, derivative suits, federal and state regulatory investigations and internal investigations

Recognition

  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021–2023 in the area of class action and in 2024 in the area of securities law. 
  • Recommended in the 2017 edition of The Legal 500 United States for his securities litigation: defense practice.
  • Consistently recognized as a Massachusetts Super Lawyer for securities litigation.

Insights & News

Credentials

  • Education

    • JD, New York University School of Law, 1996

      magna cum laude Order of the Coif; Editor, New York University Law Review
    • AB, Economics and Government, Harvard University, 1993

      magna cum laude
  • Admissions

    • Massachusetts

  • Clerkships

    • The Hon. Ronald R. Lagueux, US District Court for the District of Rhode Island, 1996 - 1997

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.